
|Videos|August 25, 2015
What Does the Future Hold for Biosimilars in the United States?
Author(s)Davy James, Managing Editor
Marc O'Connor, Chief Operating Officer of Curant Health, discusses the potential impact of biosimilars on the specialty drug market.
Advertisement
Marc O'Connor, Chief Operating Officer of Curant Health, discusses the potential impact of biosimilars on the specialty drug market.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
2
New CKD Outcome Set Tells Pharmacists What to Measure
3
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
4
The PBM Reform Clock Is Running to 2028—Here's What Independent Pharmacies Should Do
5


































































































